Two Sigma Advisers’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-505,900
| Closed | -$804K | – | 2752 |
|
|
2024
Q1 | $804K | Sell |
505,900
-81,000
| -14% | -$129K | ﹤0.01% | 1674 |
|
|
2023
Q4 | $504K | Buy |
586,900
+112,900
| +24% | +$97K | ﹤0.01% | 1921 |
|
|
2023
Q3 | $507K | Buy |
474,000
+106,600
| +29% | +$114K | ﹤0.01% | 1786 |
|
|
2023
Q2 | $952K | Sell |
367,400
-1,400
| -0.4% | -$3.63K | ﹤0.01% | 1557 |
|
|
2023
Q1 | $1.5M | Buy |
368,800
+39,300
| +12% | +$160K | ﹤0.01% | 1426 |
|
|
2022
Q4 | $1.65M | Buy |
329,500
+42,800
| +15% | +$215K | ﹤0.01% | 1333 |
|
|
2022
Q3 | $3.75M | Buy |
286,700
+89,700
| +46% | +$1.17M | 0.01% | 877 |
|
|
2022
Q2 | $2.53M | Buy |
197,000
+2,600
| +1% | +$33.3K | 0.01% | 1094 |
|
|
2022
Q1 | $2.97M | Sell |
194,400
-72,400
| -27% | -$1.1M | 0.01% | 1047 |
|
|
2021
Q4 | $4.73M | Buy |
266,800
+101,000
| +61% | +$1.79M | 0.01% | 794 |
|
|
2021
Q3 | $3.49M | Buy |
165,800
+131,600
| +385% | +$2.77M | 0.01% | 959 |
|
|
2021
Q2 | $674K | Buy |
34,200
+7,100
| +26% | +$140K | ﹤0.01% | 1811 |
|
|
2021
Q1 | $788K | Buy |
+27,100
| New | +$788K | ﹤0.01% | 1789 |
|